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ABSTRACT

Pyles, John Allen. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2009.
Characterization of Infectivity and Pathogenesis of Partially Reconstructed 1918 and
Highly Pathogenic Avian Influenza Viruses in the BALB/c Mouse Model.

Influenza viruses are consistently responsible for an average of 20,000 deaths and
114,000 hospitalizations per year. To a great extent, these viruses always stay one step
ahead of the available vaccines and people’s immunity year after year because they have
the ability to either mutate part of their genetic material, or to be transmitted from one
species to another. That same genetic variability explains why highly pathogenic
influenza viruses emerge that cause great mortality over several countries resulting in
pandemics. Highly pathogenic strains of influenza A virus have emerged occasionally in
recent history, producing pandemics such as the one in 1918. The Spanish influenza
pandemic of 1918–1919 was uniquely severe, causing an estimated 50 million deaths
worldwide. Also unique was the age distribution of its victims: the death rate for young,
previously healthy adults, who rarely suffer fatal complications from influenza, was
exceptionally high. More recently we have seen the emergence of influenza cases and
fatalities involving the H5N1 avian influenza strains. Until an outbreak in Hong Kong
claimed six human lives in 1997 (A/Hong Kong/156/97 [H5N1]), avian influenza viruses
were thought to be incapable of infecting humans directly. However, the initial H5N1
outbreak has revealed that avian influenza viruses could infect humans without prior
adaptation and even cause significant morbidity and mortality in the human population. It
iii

has been shown that the 1918 viral hemagglutinin sequence is more closely related to
avian strains although it is a human HA. This indicates that the 1918 pandemic strain may
have also jumped from avian to human with no prior adaptation or reassortment with a
human virus.
For these reasons, scientists have been interested in finding out what makes the 1918
virus different from all others, why avian influenza can be so pathogenic, and how to
prevent and better treat infections with this virus.
For this study the 1918 pandemic influenza was partially reconstructed by placing the
1918 influenza viral hemagglutinin and neuraminidase genes or the 1918 influenza viral
hemagglutinin, neuraminidase and non-structural protein genes in the background of the
low-pathogenic A/Texas/36/91 virus. The infectivity and pathogenesis of these two
partially reconstructed 1918 influenza viruses were compared to each other as well as to
the highly-pathogenic avian influenza A/Vietnam/1203/04 H5N1 virus in the BALB/c
mouse model. The A/Vietnam/1203/04 influenza virus acted as a “positive” control for
high infectivity and pathogenesis.
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Introduction

Influenza viruses are consistently responsible for an average of 20,000 deaths and
114,000 hospitalizations per year. To a great extent, these viruses always stay one step
ahead of the available vaccines and people’s immunity year after year because they have
the ability to either mutate part of their genetic material, or to be transmitted from one
species to another. That same genetic variability explains why highly pathogenic
influenza viruses emerge that cause great mortality over several countries resulting in
pandemics. Highly pathogenic strains of influenza A virus have emerged occasionally in
recent history, producing pandemics such as the one in 1918. The Spanish influenza
pandemic of 1918–1919 was uniquely severe, causing an estimated 50 million deaths
worldwide (1, 2). Also unique was the age distribution of its victims: the death rate for
young, previously healthy adults, who rarely suffer fatal complications from influenza,
was exceptionally high (1, 3). More recently we have seen the emergence of influenza
cases and fatalities involving the H5N1 avian influenza strains.
Until an outbreak in Hong Kong claimed six human lives in 1997 (A/Hong Kong/156/97
[H5N1]), avian influenza viruses were thought to be incapable of infecting humans
directly. However, the initial H5N1 outbreak has revealed that avian influenza viruses
could infect humans without prior adaptation and even cause significant morbidity and
mortality in the human population. It has been shown that the 1918 viral hemagglutinin
(HA) sequence is more closely related to avian strains although it is a human HA (1).
This indicates that the 1918 pandemic strain may have also jumped from avian to human
with no prior adaptation or reassortment with a human virus (1).
1

For these reasons, scientists have been interested in finding out what makes the 1918
virus different from all others, why avian influenza can be so pathogenic, and how to
prevent and better treat infections with this virus.
The purpose of this study is to compare the infectivity and lethality of two recombinant
1918 pandemic influenza viruses; one containing the HA and neuraminidase (NA) genes
of the 1918 influenza virus and another containing the HA, NA and non-structural
proteins (NS) genes of the 1918 influenza virus. These genes will be placed in the
background of the low pathogenic Texas/91 influenza strain. The lethality and infectivity
of these two recombinant 1918 viruses will be compared to each other as well as to the
parent Texas/91 influenza virus and the A/Vietnam/1203/04 H5N1 avian influenza
viruses in the mouse model.
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Background
Influenza is a multi-partite virus containing 7-8 negative-stranded RNA genomic
segments. These RNA segments code for ten proteins: hemagglutinin (HA),
neuraminidase (NA), non-structural proteins (NS1 and NEP), polymerase proteins (PB1,
PB2 and PA), matrix proteins (M and M2) and nucleoprotein (NP). Since the influenza
genome is in the negative sense it has to provide its own RNA-dependant RNA
polymerase in order to make RNA capable of being read by eukaryotic ribosomes. This
polymerase complex lacks proofreading capability, such that one in five virus particles
produced is likely to contain a change at one of its approximately 13,500 nucleotides
(18). If such a change provides the virus with a competitive advantage, that strain quickly
replaces its predecessor (18). In humans, the need to escape preexisting immunity exerts
positive selection pressure on changes in amino acids comprising the antigenic sites of
the surface glycoproteins, HA and (NA) (18). The process of progressive change in the
antigenic properties of the virus is called antigenic drift and results in the emergence of
an antigenically distinct variant strain every 2-3 years (18). In the pandemic influenza,
one or both of the viral surface proteins are replaced with proteins to which the human
population has no preexisting immunity (18). The virus then spreads explosively,
producing symptomatic infection in up to one third of most populations (18). This
happened with the pandemics of 1918, 1957, and 1968 with the 1918 influenza pandemic
being the most recognized and pathogenic.

Although most deaths from the 1918 pandemic were the consequence of secondary
bacterial pneumonias (there were no antibiotics available in 1918), a subset died in just a
3

few days with massive pulmonary hemorrhage or edema. Clinical symptoms and
pathological findings during the 1918 influenza pandemic were predominantly
respiratory ones. Necrotic lesions in systemic organs like those seen in virulent avian
influenza infections were not observed. Gastrointestinal symptoms and impaired hepatic
and renal function also were described.
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Hemagglutinin (HA)
Hemagglutinin (HA) is a major influenza surface glycoprotein that is involved in binding
of the host cell during infection. There are 16 different HA subtypes, all of which wild
aquatic birds are the reservoirs (4). Of the 16 HA subtypes only H1, H2 and H3 have
caused human disease and death (4). Hemagglutinin was so named because it is the
protein responsible for the ability of influenza virus to agglutinate red blood cells. HA is
now recognized as the major virulence factor associated with the influenza virus.
HA is translated as a single protein, HA0, and expressed as a trimer (5). In order for
influenza to infect the host cell, HA0 must be activated by cleavage by a trypsin-like
serine endoprotease at a specific site, normally coded for by a single basic amino acid
(usually arginine) between the HA1 and HA2 domains of the protein (5). Highly basic
amino acids in the HA binding site are associated with pathogenesis in chickens and mice
(6-8). Interestingly, the 1918 pandemic influenza virus does not have multiple basic
amino acids at the cleavage site (9). In mammals, the suspected protease in the
respiratory tract responsible for HA activation is tryptase Clara, a serine protease
produced by non-ciliated Clara cells of the bronchial and bronchiolar epithelia (5). After
cleavage, the two disulfide-bonded protein domains produce the mature form of the
protein subunits as a prerequisite for the conformational change necessary for fusion and
hence viral infectivity (5). The antigenic and receptor-binding sites of the HA1 domain
represent the most variable portion of the influenza genome (10).

Human influenza viruses attach to host cells via an N-acetylsialic acid attached to
galactose with an α-2,6 linkage, whereas avian influenza viruses mostly bind to N5

acetylsialic acid attached to galactose with an α-2,3 linkage (11). This binding specificity
of the hemagglutinin protein determines the host range of a given influenza virus (11).
Human tracheal epithelium contains mostly α-2,6 receptors whereas duck gut epithelium
contains mostly α-2,3 receptors (11). However, chicken lung and intestinal epithelial cells
contain both α-2,6 and α-2,3 receptors (11). The lack of human-to-human transmission of
avian influenza H5N1 viruses is believed to be due to their α-2,3 sialic acid receptor
binding preference (12). The three influenza pandemic viruses of the last century,
occurring in 1918 (H1N1), 1957 (H2N2) and 1968 (H3N2), each possessed an HA with a
human α-2,6 sialic acid binding preference (12).
Tumpey et al. (12) have shown that amino acids 190 and 225 in the 1918 HA determined
its binding specificity. Three influenza viruses were used in this study with differing
specificities. A/South Carolina/1/18 (SC18) was specific for α-2,6 sialic acid. A single
amino acid substitution in SC18 from aspartate to glycine at position 225 gave it a mixed
α-2,3/α-2,6 sialic acid preference designated as NY18 (12). The virus with α-2,3 sialic
acid preference (AV18) was made by substituting aspartate for glutamate at position 190
in NY18 (12). Transmission of the 1918 pandemic virus was abolished when the binding
specificity was changed from α-2,6 (human) to α-2,3 (avian) preference (12). Ferrets
inoculated with NY18 and AV18 showed severe illness and death but failed to transmit
the virus ferret-to-ferret (12). The AV18 virus also replicated in the upper respiratory
tract as efficiently as the parental SC18 virus, but it failed to transmit to contact ferrets
(12). These same amino acid changes do not confer α-2,6 preference on H5N1 avian
influenza viruses. It is therefore likely that different avian HA subtypes have different
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structural requirements to confer receptor specificity (12). It is not known which amino
acid changes will need to occur in order for H5N1 to gain α-2,6 specificity (12).
Since the HA protein is so important in determining host specificity it has been an
important focus in determining its role in the high pathogenicity of the 1918 pandemic
influenza strain. Both the 1918 HA and 1918 polymerase genes have been shown to be
essential for maximal virus replication and optimal virulence (13 - 15). In order to test
what effect the HA protein had on the pathogenicity of the 1918 pandemic virus Kobasa
et al. (15) placed the 1918 HA in the background of three different influenza strains,
A/WSN/33 (WSN), A/Kawasaki/173/2001 (K173), and A/Memphis/8/88 (M88). Mice
were inoculated intranasally with each of the three recombinant viruses. The parental
K173 and M88 caused no discernible morbidity in mice whereas the K173 and M88
strains bearing the HA from 1918 caused a lethal infection in mice (15). WSN with and
without the HA from 1918 were pathogenic. Since WSN is already highly pathogenic in
mice it could not be determined what the contribution of the 1918 HA had on the
pathogenicity of the recombinant virus (15). Infection with viruses possessing HA from
1918 was characterized by massive recruitment of polymorphonuclear cells (mainly
neutrophils) accompanied by intra-alveolar haemorrhage (15). 1918 HA was found to be
the primary determinant of enhanced pathogenicity in the recombinant viruses (15).
In mammals, like humans and swine, influenza replication is limited to epithelial cells of
the upper and lower respiratory tract. This tissue tropism is controlled to some extent by
the limited expression of the appropriate protease for viral activation of the HA protein
(5). Avian strains have been found with insertion mutations at the HA cleavage site
which allows HA to be cleaved by ubiquitously expressed proteases (5). This allows the
7

virus to be able to replicate throughout the birds body (5). This mutation inserts an
additional amino acid with a minimal motif of R/L-X-R/L-R (5). This has only been
found in avian H5 and H7 subtypes recently (5). In 1997 16 people in Hong Kong were
infected with an avian H5N1 influenza virus (5). Although the HA cleavage site mutation
had not been found previously in humans, an influenza strain with the ability to replicate
outside its normal host cells was described 50 years ago. WSN/33 was produced in 1940
by forcing the parent strain, WS/33, to replicate in mouse brain (16) to develop an animal
model for the observed neurologic complications associated with the 1918 influenza. The
strain was passaged extensively in ferrets, in chicken eggs, in mouse lung, and finally in
mouse brain. Although this strain was believed initially to be specifically pneumotropic
and neurotropic, producing a lethal encephalitis in mice, it recently has been shown to be
pantropic or capable of systemic infection in mice (17). It was found that WSN/33 had its
HA cleaved by serum plasmin found in the brain. Schulman and Palese (33) showed that
the NA protein of WSN/33 was a necessary component for HA cleavage, and in 1993, Li
et al. (34) found that the NA of WSN/33 lacked a crucial glycosylation site at residue 130
that is conserved in other influenza NA’s. The N146R change in WSN/33 alters the N-XS/T motif necessary for posttranslational glycosylation of NA (15). Plasminogen binds
specifically to the NA of WSN/33. In so doing, the WSN/33 NA sequesters plasminogen
on the cell surface so that it can be activated. Once activated, plasmin, also a serine
protease, recognizes the single arginine motif at the cleavage site and cleaves HA0 into
HA1 and HA2. WSN/33 neurovirulence also required the matrix (M) and nonstructural
(NS) segments in addition to NA. The M and NS segments seemed to act as accessory
virulence factors to enable efficient viral replication. The biological behavior of
8

neurovirulence is polygenic and cannot be fully explained by potentially pantropic HA
cleavage alone.
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Neuraminidase (NA)
Neuraminidase (NA), like hemagglutinin, is a surface-expressed glycoprotein. Along
with HA, NA plays an important role in virulence, host specificity and the human
immune response (10). NA cleaves the terminal sialic acid residues that are receptors for
the HA protein (10). Removal of sialic acids from the surface of infected cells and from
newly formed viruses prevents the budding viruses from clumping to each other or the
cell surface (19). The ability to cleave sialic acid is also thought to help the virus
penetrate mucus (20). There are nine subtypes of NA that have been identified (10). The
active site consists of 15 charged amino acids in a pocket on the surface. These amino
acids are conserved in all influenza A viruses (21). NA demonstrates more genetic
variability than other influenza genes (10). There are at least two antigenic sites in NA
(22). Mutations in these amino acids can allow the virus to escape previous immunity
(22). Shift in NA is not critical in the initiation of a pandemic, as the pandemic strain of
1968 retained the previously circulating N2 (10). However, widespread immunity to N2
is thought to have lessened the severity of the 1968 pandemic (23, 24).
Phylogenetic analyses revealed that the 1918 NA sequences are most closely related to
avian isolates, but also suggest that the 1918 sequences share enough characteristics with
mammalian isolates to distinguish them from the avian clade (10). The results of NA
analysis from the Spanish 1918 influenza virus, A/Brevig Mission/1/18 (Brevig/18),
sequence is intermediate between avian and mammalian sequences, and therefore are
consistent with the idea that pandemic viruses acquire their surface proteins directly (with
little modification) from avian viruses. There are 22 homologous amino acids in avian
10

N1’s (21). Fifteen of these 22 amino acids show variation in human N1’s (10). The
sequence of the Brevig/18 NA matches 14 of the 15 avian consensus sites (10).
Normally, neuraminidase activates latent TGF-β, a potent anti-inflammatory cytokine
that activates monocytes (4). During infection in mice with different Hong Kong H5N1
strains it was noted that there was a decrease in TGF-β activation (4). Thus, NA may help
contribute to the severe pathology of H5N1 infections in mice by decreasing TGF-β
activation in the infected host (4).
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Non-Structural Protein (NS)
The non-structural protein (NS) of influenza is so named due to the fact that it is not
incorporated into the influenza particle. Once the virus has infected a cell it will express
the NS protein. The NS protein is cleaved into two separate proteins, NS1 and NEP
(nuclear export protein). NEP is believed to aid in the export of viral nucleic acid across
the nuclear envelope of the host cell. NS1 is known to attenuate the host response
mediated by α and β interferons (25). Sang Heui Seo et al. found that H5N1 Hong Kong
strains were not inhibited by IFN-α, IFN-γ or TNF-α when added to St. Jude porcine lung
(SJPL) epithelial cells (26). When they added the NS gene of the H5N1 Hong Kong
strain A/HK/156/97 to A/PR/8/34 (H1N1) with reverse genetics they found that the
recombinant virus inherited the same cytokine resistance that the H5N1 strain had,
whereas the parent A/PR/8/34 strain was susceptible to the cytokines (26). This study
showed that it was the NS gene of H5N1 avian influenza that was imparting cytokine
resistance to the virus. They also showed that the change from aspartic acid to glutamic
acid at position 92 of NS1 was crucial for pathogenesis (26). Post-mortem reports of two
human deaths caused by H5N1/97 viruses indicated that the chief cause of death was due
to hypercytokinemia and resultant hemophagocytic syndrome due to high levels of
cytokines (26). This was also seen in non-human primates challenged with the wild-type
1918 pandemic influenza virus (35).
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Reverse Genetics
In contrast to positive-sensed RNA viruses, the naked genomic RNA of a negative-sensed
RNA virus is not able to initiate infection when expressed or transfected into a permissive
cell line (27). The minimal infectious particle of negative-sensed RNA is the
transcriptionally active ribonucleoprotein (RNP). This complex is composed of genomic
viral RNA (vRNA) along with viral nucleoprotein (NP) and the RNA-dependant RNA
polymerase (PA, PB1 and PB2) (27). The NP, PB1, PB2, and PA proteins are the only
proteins required for replication and transcription of the viral RNP’s in vivo (29). These
genomic RNPs are templates for transcription to produce naked mRNAs as well as for
replication in order to form negative-stranded RNA for encapsulation (36).

Enami et al pioneered the reverse-genetics, helper virus-dependent system for influenza
A virus (30). The influenza ribonucleoprotein (RNP) complex is generated by in vitro
vRNA synthesis in the presence of purified polymerase and NP proteins and then used to
transfect eukaryotic cells (30). Subsequent infection with influenza A helper virus results
in the generation of viruses possessing a gene derived from cloned cDNA (30).
Whereas Enami et al (30) used in vitro techniques in order to produce transfectant virus,
Neumann et al. (31) used in vivo synthesis of vRNA by RNA polymerase I (polI), a
cellular enzyme that transcribes ribosomal RNA that lacks both a 5’ cap and a 3’ poly(A)
tail (31). Transfection of cells with a plasmid containing cloned influenza virus cDNAs,
flanked by RNA polymerase I promoter and terminator sequences, followed by influenza
virus infection, led to the production of transfectant viruses (31).
13

Pleschka et al (27) designed a plasmid-based reverse genetics system to make RNP’s
without the need of a recombinant helper virus or purified proteins. Four plasmids
encoding for the P proteins (PB1, PB2 and PA) and NP, under the control of the
hydroxymethylglutaryl-coenzyme A reductase (HMG) promoter, were used to make their
respective proteins. A fifth plasmid encodes the chloramphenicol acetyltransferase (CAT)
open reading frame in a negative-sense flanked by the non-coding regions of the NS gene
of influenza A/WSN/33. A truncated human polI polymerase promoter (-250 to -1) was
fused directly to the end of the viral cDNA in order to ensure the correct 5’ end of the
vRNA. This promoter was selected by Pleschka et al. due to the success of Neumann et
al. of a similarly truncated murine polI promoter to drive the expression of influenza
virus model RNA in virus-infected cells (31). The hepatitis delta virus genomic ribozyme
was added to the 3’ end in order to ensure that the 3’ end was correct (27). These
plasmids were transfected into 293T cells which resulted in CAT protein expression. This
indicates that a negative-sense RNA can be reconstituted intracellularly into functional
RNP’s. These intracellularly reconstituted RNP’s were packed into progeny influenza
viruses when the plasmid-transfected cells were infected with influenza WSN virus.
All these methods required that the transfectants be selected from a vast background of
helper viruses, which requires a strong selection system and complicates the generation
of growth-defective viruses. Neumann et al then designed a system in which influenza
virus was made completely from cloned cDNAs (32). This reverse-genetics approach is
highly efficient and can be used to introduce mutations into any gene segment and to
develop influenza virus-based gene delivery systems. All eight cDNAs representing the
14

eight viral RNA segments were placed under the control of the human RNA polymerase I
promoter and mouse RNA polymerase I terminator in the pCAGGS plasmid (32). These
plasmids were then transfected into 293T cells along with protein expression plasmids
expressing influenza PB1, PB2, PA and NP. vRNAs and RNPs were successfully
produced along with infectious viral particles (32). Producing influenza virus from cloned
cDNAs allows for the mixing of RNA from different influenza strains. This allows for
the testing of specific genes on the pathogenicity and infectivity of influenza viruses.

15

Mice Influenza Model
Mice have been used as model hosts in a variety of viral infections. After human
infections with the highly-pathogenic H5N1 viruses in 1997 occurred, scientists started to
study the virus. No suitable host model had been established for highly-pathogenic
influenza viruses. The BALB/c mouse was found to be a suitable animal model for the
study of highly-pathogenic H5N1 human virus pathogenesis and immunity (38). The
H5N1 virus caused lethal infection and replicated in lungs of mice with no prior
adaptation, something normally required (38). Tumpey et al. showed that there was a
decrease in peripheral blood and tissue lymphocytes and aberrant cytokine and
chemokines production in mice when challenged with the H5N1 virus (39). This
demonstrated that the BALB/c mouse was a good model for the immune response to
H5N1. They also showed that there was an increase in apoptotic cells in the spleen and
lung tissue, a possible cause of lymphocyte death (39).

16

Study Objectives
This study looked at the pathogenic effects of the 1918 pandemic influenza viral HA, NA
and NS genes in the background of the low-pathogenic TX91 influenza virus. The highlypathogenic H5N1 A/Vietnam strain was used as a “positive” control for highly
pathogenic viral pathogenesis. BALB/c mice were utilized and lung titers and body
weight were determined.

17

Materials and Methods
Cells. 293T human embryonic kidney cells and Madin–Darby canine kidney cells
(MDCK) were maintained in DMEM supplemented with 10% FBS and in EMEM
containing 10% FBS, respectively. All cells were maintained in a humidified incubator at
37°C in 5% CO2.
Generation of Partially-Reconstructed Influenza. Influenza particles containing RNA
segments from the 1918 pandemic influenza virus was constructed in the background of
the innocuous influenza strain A/Texas/36/91 (TX91). In one partially reconstructed 1918
virus we placed the 1918 HA (from A/South Carolina/1/18) and NA (from A/Brevig
Mission/1/18) cDNAs in the background of TX91. In another we placed the 1918 HA
(from A/South Carolina/1/18), NA (from A/Brevig Mission/1/18) and NS (from A/Brevig
Mission/1/18) cDNAs in the background of TX91. All three of these proteins have been
determined to be influenza virulence factors.

The following plasmids were used in this study: pCAGGS-PB1, pCAGGS-PB2,
pCAGGS-PA, and pCAGGS-NP (protein expression plasmids) along with pPolI-TX91PB1, pPolI-TX91-PB2, pPolI-TX91-PA, pPolI-TX91-NP, pPolI-TX91-M, pPolI-1918HA, pPolI-1918-NA and pPolI-1918-NS (RNA polymerase I plasmids containing viral
cDNAs) (Figure 1). All plasmids were obtained from the laboratory of Dr. Garcia-Sastre,
Mount Sinai Medical Center. The eight transcription plasmids expressing the individual
vRNA genes were constructed by polymerase chain reaction (PCR), using overlapping
deoxyoligonucleotides for the genes. The coding regions are according to the open
reading frame sequences. The viral genomic sequences were cloned into the
18

pPolI.SapI.Rib vector. This vector contains the human RNA polymerase I promoter (PolI) and the hepatitis δ ribozyme (R) sequence and originated from Dr. Ervin Fodor at the
University of Oxford.

Figure 1. Schematic representation of the plasmid-based rescue system for the influenza viruses.
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Each transfection contained vRNA expression plasmids for the TX91 PA, PB1, PB2, NP,
and M segments, the appropriate vRNA expression plasmid for the 1918 HA, NA and NS
segments, and the protein expression plasmids pCAGGS-PA, -PB1, -PB2 and –NP.
Two control plasmids were also used. The pCAGGS-PB1/PB2/PA/NP/GFP control
plasmid monitored polymerase complex activity via GFP expression. The pCAGGS-GFP
control plasmid monitored transfection efficiency via GFP expression.
The 1918 HA gene sequence used in this study was obtained from formalin-fixed,
paraffin-embedded right lung tissue from a 21-year-old male stationed at Ft. Jackson,
South Carolina (A/South Carolina/1/18) (2).
The 1918 NA and NS gene sequences used in this study came from a 1918 influenza
virus isolated from an Inuit woman exhumed in permafrost in Brevig Mission in Alaska
(10). History shows that the 1918 pandemic virus swept through the village of Brevig
Mission in 5 days, leaving 72 dead (1).
The protein expression plasmids were derived by transferring the ORFs of the WSN PA,
PB1, PB2, and NP into the pCAGGS expression plasmid.
In order to make 1918 HA/NA:TX91 recombinant influenza virus, 293T/MDCK cell
mixture (7:10 ratio, respectively) were transfected with 1μg of pPolI plasmids containing
the HA and NA genes from 1918 and the remaining six genes from TX91 along with 1μg
pCAGGS plasmids containing the cDNA coding for NP, PB1, PB2 and PA proteins using
Lipofectamine 2000 (Invitrogen, Carlsbad, California).
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In order to make 1918 HA/NA/NS:TX91 recombinant influenza virus, 293T/MDCK cell
mixture were transfected with 1μg of pPolI plasmids containing the HA, NA and NS
genes from 1918 and the remaining five genes from TX91 along with 1μg pCAGGS
plasmids containing the cDNA coding for NP, PB1, PB2 and PA proteins using
Lipofectamine 2000 (Invitrogen, Carlsbad, California).
After 18-24 hours, the media was aspirated and replaced with 1x MEM containing
1μg/ml TPCK-trypsin. Plates of cells were continued to be incubated for an additional 48
hours at 37˚C and 5% CO2.
Recombinant virus was plaque-purified approximately 72 hours post-transfection.
Briefly, 500μl of transfected supernatant was added to a well of a 6-well plate of MDCK
cells and incubated 1 hour at room temperature in order to allow the virus to adsorb to the
cells. Cells were then overlaid with 3mls of 1.8% agarose and incubated at 37˚C and 5%
CO2 in order to allow virus growth. Approximately 72 hours later plaques were picked
and placed into tubes containing 1x MEM. The picked plaques were then expanded on
confluent MDCK cells.
RNA was purified with TriPure (Roche Applied Science, Indianapolis, IN) and sent to
the Mount Sinai Medical Center for sequencing in order to verify no mutations were
present in the viral genomes of the reconstructed 1918 viruses.
Identification of all genes in the reconstructed viruses was confirmed by RT-PCR and
subsequent sequencing.
Titers of the partially-reconstructed recombinant 1918 viruses were determined by
TCID50 analysis.
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Viruses. Stocks of 1918 HA/NA:TX91 and 1918 HA/NA/NS:TX91 were propagated on
Madin-Darby canine kidney cells (MDCK). The highly pathogenic A/Vietnam/1203/04
virus (A/Vietnam) was propagated in the alloantoic cavity of 10 day old hen eggs at
37°C. The alloantoic fluid from infected eggs was harvested and stored at -70oC. The
A/Vietnam virus used for challenge experiments was passed a single time in embryonated
eggs prior to use. A/Texas/36/91 (TX91) was obtained from the laboratory of Dr. Adolfo
Garcia-Sastre at the Mount Sinai Medical Center (New York, New York). Virus titers
were determined by plaque assays in MDCK cells and are expressed as plaque forming
units per milliliter (PFU/mL). All viruses were stored at -70°C until use.
Lung processing. Necropsies were carried out according to a standard protocol. Samples
for virological examination were stored at ≤-70°C. Lungs from 9 mice from each group at
each time point were homogenized in a single 50 cc tube containing minimal essential
medium (MEM) containing 100 IU of penicillin per ml, 100 mg of streptomycin per ml,
4% bovine serum albumin (fraction V; Gibco-BRL), and 4 mg of trypsin (Gibco-BRL)
(infection medium) using Potter tissue grinders. Lungs were pooled into groups of 3 so
that n=3 for each group at each time point. The supernatant was centrifuged at 700 x g for
5 minutes at 4˚C. The clarified supernatant was transferred to cryovials and stored at ≤70˚C for viral load analysis.
Mice. Female BALB/c mice (5-6 weeks of age) were purchased from Charles Rivers
Laboratories (Wilmington, MA). Mice were housed in polycarbonate filter cages inside a
Biosafety level 3 enhanced facility (BSL-3+). Food and water were provided ad libitum.
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Lethality. To confirm lethality of the partially-reconstructed 1918 HA/NA:TX91 and
1918 HA/NA/NS:TX91 virus stocks, groups of 3-7 mice were anesthetized with ketamine
and xylazine and challenged via the intranasal route (IN) in a total volume of 50
microliters with approximately 1 x 106 PFU of the 1918 HA/NA:TX91, or 1918
HA/NA/NS:TX91 virus. For purposes of comparison, groups of mice were also
challenged with 2 x 104 PFU of A/Vietnam or vehicle controls (uninfected MDCK cell
culture supernatant or alloantoic fluid). Body weights and clinical observations were
recorded daily over a 12 day period post-challenge. Animals surviving challenge were
euthanized. The experiment was repeated for the 1918 HA/NA:TX91 and TX91 viruses
using 4 serial 10-fold or 3 serial 3-fold dilutions of virus, respectively, in phosphate
buffered saline (4-6 mice for each dose/dilution).
Pathogenicity. Mice were infected with 50 microliters of either A/Vietnam (2.0 x 104
PFU), TX91 (1.1 x 106 PFU), 1918 HA/NA:TX91 (1.7 x 106 PFU), 1918
HA/NA/NS:TX91 (1.4 x 106 PFU) or vehicle controls (uninfected MDCK cell culture
supernatant or alloantoic fluid) via the intranasal route (Table 1). An additional 5 naïve
mice were anesthetized with ketamine and xylazine and a terminal blood sample taken by
heart stick one day prior to the start of the experiment. These mice served as naïve
controls. At approximately 24, 72 and 120 hours following infection 9 mice per group
were sacrificed for collection of lungs. Lungs were pooled from 3 mice per time point per
group in order to ensure sufficient sample volume for assays.
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Table 1. Stock influenza viral titers and challenge doses.

Group

Abbreviation

HA 1918 / NA 1918 / 6 genes from
A/Texas/36/91

1918
HA/NA:TX91

HA 1918 / NA 1918 / NS 1918 / 5
1918
genes from A/Texas/36/91
HA/NA/NS:TX91

1

Titer1
Challenge
(PFU/mL) dose (PFU)
3.4x107

1.7x106

2.7x107

1.4x106

A/Vietnam/1203/04 (H5N1)

A/Vietnam

1.5x108

2.0x104

A/Texas/36/91 (H1N1)

TX91

3.0x108

1.1x106

Cell culture vehicle control

CC

0

NA

Allantoic culture vehicle control

AC

0

NA

Titers calculated using the Spearman Kärber method from titrations in MDCK cells.

TCID50. In order to assess the viral load in the lungs Tissue Culture Infectious Dose 50
(TCID50) assay was used. Lung homogenates were added to 96-well plates seeded with
MDCK cells. Three samples were assayed per group per time point. Samples were
diluted 1:10 initial dilution and then nine times at 1:5 for a total of ten dilutions. Five
replicates of each dilution were plated. Samples were incubated in a humidified incubator
at 37˚C and 5% CO2 for approximately 72 hours. Results were calculated using Spearman
Kärber method.
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Results
Reconstruction. Genes encoding the 1918 pandemic influenza virus were reconstructed
from deoxyoligonucleotides and corresponded to the reported 1918 coding sequences (2,
10, 37). Partially-reconstructed 1918 influenza viruses were produced by transfecting the
appropriate plasmids from the 1918 pandemic virus and the Texas/91 virus into a
293T/MDCK cell culture mixture. Control plasmids containing a GFP marker were used
in order to verify that the viral polymerase was produced and functional for viral RNA
replication. Approximately 24 hours post-transfection the control transfections were
viewed under a fluorescence microscope for GFP production. It was verified that the
transfections were successful and that the influenza RNA-dependant RNA polymerase
was being produced and was functional (Figure 2).

Figure 2. 293T/MDCK cells transfected with pCAGGS-PB1/PB2/PA/NP/GFP
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Appropriate 1918 HA/NA:TX91 and 1918 HA/NA/NS:TX91 clones were chosen based
on genomic RNA yield, sequence analysis, hemagglutination assay results, stock viral
concentration and lethality in mice.

Infectivity. The HA, NA and NS genes of the 1918 pandemic influenza virus rescued in
the genetic background of TX91 virus had high infectivity titers in MDCK cells similar to
those of the wild-type TX91 virus. See Table 1.

Lethality Determination. To determine the lethality of the 1918 HA/NA:TX91
construct, serial 10-fold dilutions of virus were inoculated into groups of four mice (1.7 x
106 -1.7 x 103 PFUs; Figure 3). The results demonstrate that the virus was 100% lethal at
1.7 x 106 PFU and 1.7 x 105 PFU. The 1918 HA/NA:TX91 construct was also lethal at
1.7 x 104 PFU, although not 100%. By comparison, challenge with undiluted (1 x 106
PFU) 1918 HA/NA/NS:TX91 resulted in only approximately 50% mortality (Figure 4).
The parent TX91 virus was also tested and was found not to be lethal.
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Figure 3. Lethality determination of 1918 HA/NA:TX91. BALB/c mice were inoculated intranasally with
serial dilutions of 1918 HA/NA:TX91 from 1.7x106 PFU to 1.7x103 PFU and monitored for 14 days for
survival.
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Figure 4. Lethality determination of 1918 HA/NA/NS:TX91. BALB/c mice were inoculated intranasally
with 1.4x106 PFU of 1918 HA/NA/NS:TX91 and monitored for 14 days for survival.
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Pathogenicity. To better understand the differences in pathogenecity among the
recombinant 1918 viruses, we examined the mortality time course post-challenge (Figure
5) and percent weight loss (Figure 6) over the course of 14 days, and viral replication in
the lungs at 24, 72 and 120 hours post-challenge (p.c.) (Figure 7).

Figure 5. Time course of mortality following challenge. BALB/c mice were challenged with 1.7x106 PFU
(1918 HA/NA:TX91), 1.4x106 PFU (1918 HA/NA/NS:TX91), 1.1x106 PFU (TX91), 2x104 PFU
(A/Vietnam), and 50µl cell culture and allantoic fluid controls.
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Figure 6. Change in body weight following challenge. BALB/c mice were challenged with 1.7x106 PFU
(1918 HA/NA:TX91), 1.4x106 PFU (1918 HA/NA/NS:TX91), 1.1x106 PFU (TX91), 2x104 PFU
(A/Vietnam), and 50µl cell culture and allantoic fluid controls

Figure 7. Mean viral lung titers (Tissue Culture Infectious Dose50) in BALB/c mice. Mice were
challenged with 1.7x106 PFU (1918 HA/NA:TX91), 1.4x106 PFU (1918 HA/NA/NS:TX91),
1.1x106 PFU (TX91), and 2x104 PFU (A/Vietnam).
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The A/Vietnam virus was highly pathogenic in the BALB/c mouse. Substantial weight
loss was observed by day 5 post-challenge (31%) and all animals succumbed prior to day
7 (Figure 6). Similarly, mice challenged with the 1918 HA/NA:TX91 virus lost
approximately 23% body weight by day 5 post-challenge and all mice succumbed prior to
day 11. The 1918 HA/NA/NS:TX91 virus was less pathogenic in that challenge with
approximately 1 x 106 PFU resulted in 15-16% weight loss by day 5 and 50% mortality.
Interestingly, results for mice challenged with the parent 1 x 106 PFU of TX91 were
similar to those obtained for vehicle controls. Mice in the TX91 and vehicle control
groups gained weight following challenge and all animals survived.

All mice challenged with cell culture control, allantoic fluid control and TX91 survived
challenge (Figure 5). Only about 50% of mice challenged with 1918 HA/NA/NS:TX91
survived challenge through day 14. These were the same results seen in the LD50 study at
the same dose. Mice challenged with A/Vietnam and 1918 HA/NA:TX91 started dying
by day 4 post-challenge. By day 7 p.c. all mice challenged with A/Vietnam had died and
by day 11 p.c. all mice challenged with 1918 HA/NA:TX91 had died. We can see that the
1918 HA/NA:TX91 recombinant virus is as lethal as A/Vietnam but with slower kinetics.
The 1918 HA/NA/NS:TX91 virus was more lethal than the parent TX91 virus, but not as
lethal as the 1918 HA/NA:TX91 recombinant virus or the highly-pathogenic A/Vietnam
influenza virus strain. It appears that the addition of the 1918 NS gene attenuates the
virus. This attenuation has been seen in previous studies in mice (37).
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Influenza virus was detected in the lungs of mice challenged with A/Vietnam, TX91 and
both 1918 reassortants at 24 hours (Figure 7). The highest viral titers were detected in
mice at 24 hours p.c. with 1918 HA/NA:TX91 (3.89 x 106 TCID50/ml)(Table 2). Lung
titers in these mice remained high at 72 and 120 hours p.c. (1.26 x 105 TCID50/ml and
4.55 x 105 TCID50/ml, respectively). These lung titers were comparable at all time points
to the highly-pathogenic A/Vietnam virus (Table 2). Lung titers in mice challenged with
the 1918 HA/NA/NS:TX91 virus were lower than the 1918 HA/NA:TX91 virus at all
time points. By 120 hours p.c., virus was undetectable in the lungs of mice challenged
with the 1918 HA/NA/NS:TX91 virus. Lung titers in mice challenged with TX91 were
lower, but comparable to mice challenged with the 1918 HA/NA/NS:TX91 virus at all
time points. Vehicle control samples were uniformly negative for virus in the TCID50
assay.
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Table 2. Lung titers at 24, 72, and 120 hours post-challenge in BALB/c mice challenged with influenza
viruses.

Group

1918 HA/NA:TX91

1918 HA/NA/NS:TX91

A/Vietnam

TX91

Cell Culture Control

Allantoic Fluid Control

Time
Geometric
Point
Mean
(hours)
24
3.89x106
72
1.26x105
120
4.55x105
24
1.64x104
72
4.78x104
120
0
24
1.13x106
72
2.52x105
120
7.78x105
24
9.21x102
72
1.12x103
120
0
24
0
72
0
120
0
24
0
72
0
120
0
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95% Confidence Interval
(2.45x106, 6.18x106)
(2.87x103, 5.49x106)
(1.23x104, 1.68x107)
(2.18x103, 1.23x105)
(2.88x103, 7.94x105)
(--)
(1.51x105, 8.43x106)
(1.59x105, 3.99x105)
(4.91x105, 1.23x106)
(7.02x10-3, 1.21x108)
(1.35x102, 9.26x103)
(--)
(--)
(--)
(--)
(--)
(--)
(--)

Statistical analysis of TCID50 Data
In order to determine if the difference in lung titers amongst groups were statistically
significant, an analysis of variance (ANOVA) model was performed. The p-value was <
0.5 for each time point, indicating that there was a difference between at least two of the
groups (Table 3). In order to determine which groups were significantly different,
Tukey’s pairwise comparisons were carried out. We see from the Tukey’s calculations
that that all groups had a statistically significant difference in viral lung titers except
between groups one and two at 24 hours post-challenge (Table 3).

A reduced data set was also created that shows the 1918 HA/NA:TX91, 1918
HA/NA/NS:TX91 and the A/Vietnam viruses as compared to the TX91 virus (Table 4).
You can see from this data set that the mean titers of all three viruses were higher than
the TX91 virus at all time points. In this reduced data set, groups that had reported values
that were all less than the LOD at a particular time point were not included in the analysis
for that time point. The complete allantoic fluid and cell culture control groups (group 5
and 6, respectively), 1918 HA/NA/NS:TX91 (group 2) on study day 5, and TX91 (group
4) on study day 5 were removed because all observations were less than the LOD.
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Table 3. Summary of ANOVA results and Tukey’s Pairwise.

ANOVA
Time Point Group
(hours)
Effect P
value

24

<0.0001

72

<0.0001

120

<0.0001

Tukey*
7.77x105 (5<1) <0.0001
3.27x103 (5<2) 0.0034
2.25x105 (6<3) <0.0001
2.38x102 (2<1) 0.0499
4.22x103 (4<1) 0.0026
1.22x103 (4<3) 0.0092
2.51x104 (5<1) <0.0001
9.57x103 (5<2) <0.0001
2.24x102 (5<4) <0.0001
5.03x104 (6<3) <0.0001
1.12x102 (4<1) 0.0002
4.28x101 (4<2) 0.0017
2.25x102 (4<3) <0.0001
9.09x104 (5<1) <0.0001
1.56x105 (5<3) <0.0001
1.56x105 (6<3) <0.0001
9.09x104 (2<1) <0.0001
9.09x104 (4<1) <0.0001
1.56x105 (2<3) <0.0001
1.56x105 (4<3) <0.0001

Group 1 = 1918 HA/NA:TX91, Group 2 = 1918 HA/NA/NS:TX91, Group 3 = A/Vietnam, Group 4 =
TX91, Group 5 = Cell culture control, Group 6 = Allantoic fluid control
*

Cells contain all pairwise differences between all groups that are statistically significant at 0.05. The
format within each cell is (1) the ratio of geometric means, (2) the relationship of the corresponding pair of
group geometric means shown in parentheses [For example, “(1<2)” indicates that the geometric mean for
group 1 was less than that for group 2], and (3) the Tukey-adjusted P-value.
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Table 4. Summary of ANOVA results and Tukey’s Pairwise. Comparisons for reduced data set

Time Point
(hours)

Group
Effect P
value

24

0.0105

72

0.001

120

0.5602

Tukey*
4.22x103 (4<1) 0.0130
1.22x103 (4<3) 0.0301
1.12x102 (4<1) 0.0024
4.28x101 (4<2) 0.0097
2.25x102 (4<3) 0.0010

Group 1 = 1918 HA/NA:TX91, Group 2 = 1918 HA/NA/NS:TX91, Group 3 =
A/Vietnam, Group 4 = TX91
Cells contain all pairwise differences between all groups that are statistically significant
at 0.05. The format within each cell is (1) the ratio of geometric means, (2) the
relationship of the corresponding pair of group geometric means shown in parentheses
[For example, “(1<2)” indicates that the geometric mean for group 1 was less than that
for group 2], and (3) the Tukey-adjusted P-value.
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Discussion
Highly pathogenic pandemic influenza viruses cause high mobidity and mortality in the
human population. This study investigated the virulence factors of the 1918 pandemic
influenza. The objective was to measure the change in pathogenesis of the low
pathogenic A/Texas/36/91 influenza when the HA, NA, and NS genes of the 1918
pandemic influenza were added.

Tumpey et al. showed that placing the 1918 HA and NA genes together in the
background of A/WSN/33 (WSN) caused lethality in mice that was equivalent to the
parent WSN virus (57). However, when 1918 HA and NA were placed in the background
of WSN individually it caused an attenuation of the virus (57). When Kobasa et al. (15)
placed the 1918 HA gene in the background of A/Kawasaki/173/2001 (H1N1) (K173)
and A/Memphis/8/88 (H3N2) (M88), they found that the 1918 HA was lethal by itself.
They also found that the 1918 NA alone in the background of K173 and M88 was no
more pathogenic than the parent strains. These studies suggested that the main lethal
factor was the 1918 HA, not 1918 NA. We found that when 1918 HA and NA were
placed together in the background of the low-pathogenic TX91 strain the virus was 100%
lethal, whereas the parental TX91 strain was not. One of our objectives in this study was
to determine the pathogenecity of recombinant viruses possessing genes from the 1918
pandemic influenza as compared to the highly-pathogenic avian influenza
A/Vietnam/1203/2004 strain. The lung titers of mice challenged with the 1918
HA/NA:TX91 virus were comparable to A/Vietnam at all time points, with 1918
HA/NA:TX91 virus being higher at 24hours p.i. than the 1918 HA/NA/NS:TX91 virus.
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The influenza NS1 protein is a known IFN-antagonist (40, 41, 25) and is required for
influenza A virus virulence (25, 42). It has been shown that the binding of the NS1 viral
protein to double-stranded RNA (dsRNA) (58) prevents the activation of multiple
proteins, including PKR (43-45). PKR is activated by dsRNA (61) which in turn
phosphorylates eukaryotic translation initiation factor 2 (eIF2α) (43). This prevents
cellular translation from being turned off and viral proteins continue to be produced. PKR
also plays a role in activating NF-κB (59) and IFN regulatory factor 3 (IRF-3) (41), both
which are important transcription factors for the initiation of the IFN-α/β cascade.
Another way NS1 prevents PKR activity is through directly binding the PKR protein
(48). So, the binding of NS1 to PKR and dsRNA contributes to the pathogenecity of the
virus by preventing the activation of the IFN-α/β cascade. This prevents the cells first line
of defense against viral infection and allows the virus to overcome the initial immune
response.

Another way the NS1 viral protein affects the host cell is by preventing the transport of
mRNAs from the nucleus (63, 64). The NS1 protein binds to the poly(A) sequence at the
3' ends of mRNAs and inhibits the nuclear export of all poly(A)-containing viral and
cellular mRNAs (65). NS1 not only prevents the export of mRNAs, but also prevents
post-transcriptional splicing of pre-mRNAs (62). NS1 does this by binding to the U6
small nuclear RNA (snRNA) (62). NS1 allows the pre-mRNA to associate with the U1,
U2, U4, U5, and U6 snRNAs to form spliceosomes but then remains associated with
these spliceosomes to inhibit the catalytic steps of splicing that are normally carried out
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by spliceosomal components (62). By preventing pre-mRNA splicing and mRNA
transport the host cell cannot produce anti-viral proteins in the cytoplasm.

One of the distinctive clinical characteristics of the 1918 influenza virus was its ability to
rapidly produce extensive damage to the respiratory epithelium (46). This is
representative of a virus that is able to overcome the initial host immune response and to
replicate to high titers and spread quickly from cell to cell. An NS1 protein that was
especially effective at blocking the type I IFN system might have contributed to the
exceptional virulence of the 1918 strain (25, 47).

We found that the addition of the 1918 NS, along with 1918 HA and NA, in the
background of TX91 attenuated the virus. Lung titers in mice infected with 1918
HA/NA/NS1:TX91 were lower than 1918 HA/NA:TX91 or A/Vietnam at 24 hours,
although the titers were still higher than mice challenged with TX91. Lung titers were
comparable to TX91 lung titers at 72 hours. By 120 p.i., virus was undetectable in lungs
of mice challenged with 1918 HA/NA/NS1:TX91 and TX91.

When the 1918 pandemic NS1 gene was placed in the background of the WSN strain of
influenza, lung titers were higher than those challenged with the wild-type WSN virus
(37). It has been shown that the NS1 protein of influenza is a virulence factor that
interacts with the host immune system, attenuating the host immune response and thus
allowing the virus to replicate unimpeded (25). We have demonstrated that NS1
originating from the 1918 pandemic virus attenuates viral replication in mice, as noted
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previously (37). It has been mentioned that this could be due to the NS1 protein being
host-specific (37).

The attenuating effect of NS1 in mice could be caused by relatively poor protein stability
in mouse cells or by the inefficient interaction of either protein with specific host factors
(37). The ability of NS1 to affect the host IFN response may involve the binding of RNA
by NS1 (40, 41, 43) or its interaction with specific proteins, including PKR (48).
Possibly, the interactions of the 1918 NS1 protein with mouse PKR and/or other
components of the type I IFN system is inefficient (48). The NS1 protein has been
reported to interact with numerous other host-cell proteins (49-56). How the NS1 antiIFN function is affected by interaction of NS1 with host-cell proteins is not clear (37).
The mouse immune system may also have a pathway not present in humans that allows it
to circumvent the effects of the NS1 protein. The mouse may also lack some of the
proteins that NS1 normally interacts with. This would limit the capability of the NS1
protein in its antagonism.

Viral titers for A/Vietnam remained high throughout the 120 hours examined suggesting
that the immune system was attenuated, thus preventing the mice from clearing the virus
by 120 hours post-infection.

The titers in lungs of mice challenged with TX91 were comparable to those challenged
with the 1918 HA/NA/NS:TX91 virus suggesting that the HA and NA genes from the
1918 pandemic strain confer high pathogenicity to the virus.
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Summary
We have shown that the addition of the 1918 HA and NA genes to the low-pathogenic
TX91 influenza strain increased its pathogenecity nearing that of the A/Vietnam H5N1
avian strain. Lung titers in mice challenged with 1918 HA/NA:TX91 were comparable to
the highly pathogenic A/Vietnam strain at all time points of the study. All mice
challenged with A/Vietnam died by day 7 whereas all mice challenged with 1918
HA/NA:TX91 died by day 11. As has been shown previously, when we added the 1918
NS to the TX91 the virus was attenuated. No mice died until day 8 in this group. It is
worthwhile to further investigate the molecular interactions the NS1 viral protein has
with host proteins in order to elucidate the cause of attenuation in mice, as well as
virulence in humans. The NS1 protein could also be an attractive target for anti-viral
treatments.
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